I guess the answer is further down in same area of the article. Refers to sarepta use of "naked PMO" so you are spot on hottod. Maybe they do need our cpp??
This approach has been used successfully with naked PMO that resulted in the conditional approval of Eteplirsen, a PMO targeting exon 51 of the DMDgene [42]. However, despite the safe profile of this drug and evidence of dystrophin production, a limitation was the relatively low treatment efficacy, with restoration of dystrophin an average of 0.9% of normal levels following 180 weeks treatment.
I guess the answer is further down in same area of the article....
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.20 |
Change
0.050(4.35%) |
Mkt cap ! $699.9M | |||
| Open | High | Low | Value | Volume |
| $1.16 | $1.21 | $1.13 | $387.7K | 327.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2000 | $1.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.20 | 25000 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |